An FDA-designated Breakthrough Therapy, AndexXa is in development for patients treated with a direct (apixaban, rivaroxaban, or edoxaban) or indirect (enoxaparin) Factor Xa inhibitor when reversal of anticoagulation
As part of the collaboration, Xenetic’s proprietary IMUXEN Technology will be used to develop the vaccine. Excivion is a private UK company that has developed a proprietary antigen design
The ability to control DNA repair outcomes has significant implications for the use of CRISPR-Cas9 in product development. The study is published in the current edition of Molecular
The TACTT2 trial did not meet the two co-primary efficacy endpoints of statistically significant changes in tinnitus loudness and tinnitus burden compared to placebo. Data from the TACTT2
Cinqaero is a humanized interleukin-5 antagonist monoclonal antibody for add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus another medicinal product for
The most significant is new technology for Direct Clinical Document Architecture (CDA) Automation of reporting to the Centers for Disease Control and Prevention's (CDC) National Healthcare Safety Network
The Foam Assets include US rights to Fabior and Sorilux, Canadian rights to Luxiq® and Olux-E® and Mexican rights to betamethasone foam. Under the terms of the agreement
Eleven has granted Roche an exclusive, worldwide license to develop and commercialize EBI-031 and all other IL-6 antagonist antibody technology owned by Eleven. EBI-031 is a humanized monoclonal
The new buildings almost double the Company's overall footprint, which increases from 9,500 to 18,500 sq ft, including new state-of-the-art laboratory facilities. The new laboratories and office space
The collaboration, facilitated by Johnson & Johnson Innovation, is focused on further understanding applications of Xycrobe's platform technology developed for the treatment of inflammatory skin diseases. The planned
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.